Supplementary Table 3. Clinical characteristics of 8 patients

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Age (years)  | Sex | Ishak | METAVIR | ALT(IU/L) | AST(IU/L) | TBIL(μmol/L) | ALB(g/L) | diagnosed  | Antiviral treatment |
| 38 | Male | 0 | 0 | 25 | 24.1 | 18 | 31.6 | HBV | TAF |
| 27 | Male | 1 | 1 | 8.8 | 14.2 | 19.7 | 41.5 | HBV | NO |
| 42 | Male | 1 | 1 | 13.2 | 17.6 | 19 | 37.6 | HBV | TAF |
| 67 | Male | 5 | 4 | 24.5 | 60.6 | 24.5 | 31.3 | HBV, HCC | TDF |
| 46 | Femal | 6 | 4 | 13.7 | 31.6 | 38.4 | 28.7 | HBV, HCC | TDF |
| 70 | Male | 5 | 4 | 16.2 | 31.6 | 23.2 | 30.7 | HBV, HCC | TDF |
| 56 | Femal | 6 | 4 | 18.5 | 30.6 | 9.4 | 28.9 | HBV, HCC | TAF |
| 48 | Male | 6 | 4 | 45.5 | 38.3 | 9.9 | 27.5 | HBV, HCC | TDF |

AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; TBIL, total bilirubin; ALB, albumin; NO, without antiviral treatment; TAF, tenofovir alafenamide fumarate; TDF, tenofovir disoproxil fumarate.